Kerr Drug to Deploy Mirixa Technology for Clinical Services
RESTON, Va., Aug. 18 /PRNewswire/ -- The Mirixa Corporation is pleased to announce that Kerr Drug has signed a licensing agreement for MirixaEdge(SM), Mirixa's clinical application that supports the delivery of pharmacist-based patient care services, including Medication Therapy Management (MTM). Awarded a grant to support delivery of patient care services by community pharmacists, Kerr will be offering MTM services to the City of Charleston, SC and Charleston Water Works employees and will utilize MirixaEdge as the technology platform for this effort.
Kerr evaluated a number of MTM platforms to support the grant initiative. Central to the decision to partner with Mirixa was the robustness of the MirixaEdge application functionality. Rebecca W. Chater, RPh, MPH, FAPhA, Executive Vice President for Kerr Drug feels the MirixaEdge software with its programmatic approach to chronic disease management is in alignment with Kerr's focus on developing new clinical services. "In order to ensure consistency of clinical service delivery across our pharmacies, we need a tool like MirixaEdge to provide the framework for guiding an interactive discussion between the pharmacist and the patient. The MirixaEdge application has the right level of structure, along with disease-specific inquiries, that will be of great benefit to our customers and staff."
Kerr Drug will utilize the Mirixa technology to track the progress of employee medication regimens, to provide patient educational information, and to report on outcomes achieved through MTM service delivery. Kerr has established itself as a leader in providing pharmacist-supervised patient care services and this grant will hel